摘要
目的:观察莫西沙星短疗程治疗慢性支气管炎细菌感染急性发作(ABECB)的临床疗效。方法:将74例ABECB患者随机分为两组,治疗组用莫西沙星400mg,po.qd,治疗5d;对照组用克拉霉素500mg,po.bid,治疗5d。观察临床指标、细菌学、临床疗效及安全性。结果:治疗组与对照组的有效率分别为91.9%和78.4%,细菌清除率为89.2%和75.7%,两组比较差异有显著性(P<0.05)。结论:莫西沙星在短疗程下治疗慢性支气管炎急性细菌加重的疗效显著,是一种广谱、安全的抗菌药物。
OBJECTIVE To compare the efficacy and safety of moxifloxacin with clarithromycin for the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB) in short course therapy. METItODS Seventy-four cases with ABECB were randomly divided into treatment group (moxifloxacin group) and control group (clarithromycin group), with 37 cases in each group. The efficacy and safety of the two groups were investigated. RESULTS The effective rate and bacteria eradication rate were 91.9% and 89. 2% respectively in moxifloxacin group and 78. 4% and 75.7% respectively in clarithromycin group, with significant difference between them(P〈0. 05). CONCLUSION Moxifloxacin is a broad-spectrum and safe antibiotic and has significant effect in short course therapy for the treatment of acute bacterial exacerbations of chronic bronchitiS, and can be taken as the first choice drug on this disease.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2008年第3期221-223,共3页
Chinese Journal of Hospital Pharmacy